Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Fedratinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,836Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva Pharma`s Generics Fedratinib Receives Tentative Approval in US
    Teva Pharma`s Generics Fedratinib Receives Tentative Approval in US

    07 Nov 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218907

    FDA
    07 Nov 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Fedratinib Hydrochloride
    FDA Confirms Paragraph IV Patent Litigation for Fedratinib Hydrochloride

    21 Sep 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-fedratinib-hydrochloride-35752.pdf

    FDA
    21 Sep 2023
    Share Share
    NICE recommends Inrebic for rare blood cancer
    NICE recommends Inrebic for rare blood cancer

    19 Nov 2021

    // PHARMATIMES

    https://www.pharmatimes.com/news/nice_recommends_inrebic_for_rare_blood_cancer_1383756

    PHARMATIMES
    19 Nov 2021
    Share Share
    Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib)
    Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib)

    11 Dec 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201211005278/en

    BUSINESSWIRE
    11 Dec 2020
    Share Share
    BMS's Receives Positive CHMP Opinion for Inrebic® (fedratinib)
    BMS's Receives Positive CHMP Opinion for Inrebic® (fedratinib)

    11 Dec 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201211005278/en/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Inrebic%C2%AE-fedratinib-for-Adult-Patients-with-Newly-Diagnosed-and-Previously-Treated-Myelofibrosis

    BUSINESSWIRE
    11 Dec 2020
    Share Share
    Health Canada Approves INREBIC® (fedratinib), First New Treatment in Nearly
    Health Canada Approves INREBIC® (fedratinib), First New Treatment in Nearly

    21 Sep 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/health-canada-approves-inrebic-and-174-fedratinib-first-new-treatment-in-nearly-a-decade-for-patients-living-with-myelofibrosis/

    BIOSPACE
    21 Sep 2020
    Share Share